Marburg I polymorphism of factor VII-activating protease is associated with idiopathic venous thromboembolism

59Citations
Citations of this article
19Readers
Mendeley users who have this article in their library.

This article is free to access.

Abstract

The factor VII-activating protease (FSAP) variant Marburg I is known to attenuate the profibrinolytic system in vitro and was recently shown to be a significant predictor for the evolution and progression of carotid stenosis. The objective of this case-control study was to assess FSAP Marburg I's role in the occurrence of venous thromboembolism (VTE). The frequency of FSAP Marburg I was significantly increased in patients with a history of VTE (17 of 213 patients, 8.0%, P = .014) or idiopathic VTE (12 of 103 patients, 11.7%, P = .002) compared to healthy controls (5 of 213 controls, 2.3%). Logistic regression analysis confirmed FSAP Marburg I to be an independent risk factor for VTE (odds ratio, 3.5; 95% confidence interval [CI], 1.2-10.0) and idiopathic VTE (odds ratio, 6.2; 95% CI, 2.0-18.9). © 2005 by The American Society of Hematology.

Cite

CITATION STYLE

APA

Hoppe, B., Tolou, F., Radtke, H., Kiesewetter, H., Dörner, T., & Salama, A. (2005). Marburg I polymorphism of factor VII-activating protease is associated with idiopathic venous thromboembolism. Blood, 105(4), 1549–1551. https://doi.org/10.1182/blood-2004-08-3328

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free